Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Financial Officer Scott L. Burrows completed a series of equity transactions on July 1, 2026, resulting in the sale of 7,500 shares of the company's common stock. The total proceeds from these sales amounted to $658,039. The divestment activity was facilitated through the exercise of stock options, which allowed Burrows to acquire an equivalent number of shares prior to the sale.
The transactions were executed in accordance with a Rule 10b5-1 trading plan, which was formally adopted on November 10, 2025. This pre-arranged framework typically insulates insiders from allegations of trading based on material non-public information. The sales were divided into two distinct blocks. The first block consisted of 5,775 shares sold at a weighted average price of $87.55 per share, with individual transaction prices fluctuating between $87.13 and $88.05. The second block involved the sale of 1,725 shares at a weighted average price of $88.37 per share, with prices ranging from $88.17 to $89.01.
These sales occur against a backdrop of substantial price appreciation for Spyre Therapeutics. The company's stock has surged approximately 450% over the trailing twelve months. Despite this momentum, current valuation metrics suggest the stock may be trading above its fair value estimate. InvestingPro analysis highlights a high Price/Book multiple of 14.61, indicating that the stock's valuation has expanded significantly relative to its book value. The stock's recent performance has drawn attention from valuation tools that utilize multiple models to assess intrinsic worth.
Before executing the sales, Burrows had acquired the 7,500 shares through the exercise of stock options at a strike price of $14.50 per share, totaling an investment of $108,750. These options were part of a broader grant initially covering 404,857 shares, which is subject to a structured vesting schedule. Following the completion of these transactions, Burrows directly holds 97,994 shares of Spyre Therapeutics common stock. This direct ownership stake includes 67,476 restricted stock units (RSUs). These RSUs represent contingent rights to receive shares upon vesting in two equal installments scheduled for September 1, 2026, and September 1, 2027, contingent upon Burrows maintaining his employment with the company.
Insider activity at Spyre Therapeutics extends beyond executive transactions. Fairmount Healthcare Fund II L.P. recently reported selling over 4.6 million shares, valued at approximately $399.7 million, signaling significant portfolio rebalancing by major institutional holders.
The financial transactions coincide with notable clinical developments for the biotech firm. Spyre reported positive results from a phase 2 trial for its experimental drug SPY002, which is designed to treat moderately-to-severely active ulcerative colitis. The trial, identified as the SKYLINE trial, demonstrated a statistically significant reduction in the Robart's Histopathology Index score. Furthermore, the company has completed enrollment for the SKYWAY basket trial, which evaluates SPY072 across various rheumatic diseases. Data from this basket trial is expected to emerge in 2026.
Wall Street analysts have responded to these clinical milestones with increased optimism. Deutsche Bank raised its price target for Spyre to $115, maintaining a Buy rating, following a setback experienced by a competitor. Similarly, Stifel increased its price target to $107, also maintaining a Buy rating, citing strong data from the ulcerative colitis trials.